Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 49 |
| Active Pipeline (Recruiting Now) | 23 (11) |
| Completed vs Stopped Early | 17 / 0 (0.0%) |
| Median Closed Actual Enrollment | 104 participants |
| Physical Hospital Site Disclosure | 98.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Peking University People's Hospital | Beijing, Beijing Municipality | 12 |
| Beijing Children's Hospital, Capital Medical University | Beijing | 4 |
| West China Hospital of Sichuan University | Chengdu, Sichuan | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04805411 | Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Keymed Biosciences Co Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.